Literature DB >> 10554098

Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles.

A E Gulyaev1, S E Gelperina, I N Skidan, A S Antropov, G Y Kivman, J Kreuter.   

Abstract

PURPOSE: To investigate the possibility of delivering of anticancer drugs into the brain using colloidal carriers (nanoparticles).
METHODS: Rats obtained 5 mg/kg of doxorubicin by i.v. injection in form of 4 preparations: 1. a simple solution in saline, 2. a simple solution in polysorbate 80 1% in saline, 3. bound to poly(butyl cyanoacrylate) nanoparticles, and 4. bound to poly(butyl cyanoacrylate) nanoparticles overcoated with 1% polysorbate 80 (Tween 80). After sacrifice of the animals after 10 min, 1, 2, 4, 6, and 8 hours, the doxorubicin concentrations in plasma, liver, spleen, lungs, kidneys, heart and brain were determined after extraction by HPLC.
RESULTS: No significant difference in the body distribution was observed between the two solution formulations. The two nanoparticle formulations very significantly decreased the heart concentrations. High brain concentrations of doxorubicin (>6 microg/g) were achieved with the nanoparticles overcoated with polysorbate 80 between 2 and 4 hours. The brain concentrations observed with the other three preparations were always below the detection limit (< 0.1 microg/g).
CONCLUSIONS: The present study demonstrates that the brain concentration of systemically administered doxorubicin can be enhanced over 60-fold by binding to biodegradable poly(butyl cyanoacrylate) nanoparticles, overcoated with the nonionic surfactant polysorbate 80. It is highly probable that coated particles reached the brain intact and released the drug after endocytosis by the brain blood vessel endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10554098     DOI: 10.1023/a:1018983904537

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  17 in total

1.  The interaction of some centrally active drugs with the blood-brain barrier and circumventricular organs.

Authors:  D J Begley
Journal:  Prog Brain Res       Date:  1992       Impact factor: 2.453

Review 2.  Recent developments in peptide drug delivery to the brain.

Authors:  W M Pardridge
Journal:  Pharmacol Toxicol       Date:  1992-07

3.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

Authors:  C Cordon-Cardo; J P O'Brien; D Casals; L Rittman-Grauer; J L Biedler; M R Melamed; J R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  Liposome targeting to mouse brain: mannose as a recognition marker.

Authors:  F Umezawa; Y Eto
Journal:  Biochem Biophys Res Commun       Date:  1988-06-30       Impact factor: 3.575

5.  Pharmacological effects of phosphatidylserine liposomes: regulation of gylcolysis and energy level in brain.

Authors:  E Bigon; E Boarato; A Bruni; A Leon; G Toffano
Journal:  Br J Pharmacol       Date:  1979-06       Impact factor: 8.739

6.  Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.

Authors:  R N Alyautdin; V E Petrov; K Langer; A Berthold; D A Kharkevich; J Kreuter
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

7.  Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts.

Authors:  E A Neuwelt; P A Barnett; K E Hellström; I Hellström; C I McCormick; F L Ramsey
Journal:  J Nucl Med       Date:  1994-11       Impact factor: 10.057

8.  Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles.

Authors:  J Kattan; J P Droz; P Couvreur; J P Marino; A Boutan-Laroze; P Rougier; P Brault; H Vranckx; J M Grognet; X Morge
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

9.  Targeting chemotherapy for malignant brain tumor using thermosensitive liposome and localized hyperthermia.

Authors:  K Kakinuma; R Tanaka; H Takahashi; M Watanabe; T Nakagawa; M Kuroki
Journal:  J Neurosurg       Date:  1996-02       Impact factor: 5.115

10.  Reversal of multidrug resistance by surfactants.

Authors:  D M Woodcock; M E Linsenmeyer; G Chojnowski; A B Kriegler; V Nink; L K Webster; W H Sawyer
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

View more
  69 in total

Review 1.  Functionalized carbon nanotubes for potential medicinal applications.

Authors:  Yi Zhang; Yuhong Bai; Bing Yan
Journal:  Drug Discov Today       Date:  2010-05-06       Impact factor: 7.851

2.  Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles.

Authors:  Supriya D Mahajan; Indrajit Roy; Gaixia Xu; Ken-Tye Yong; Hong Ding; Ravikumar Aalinkeel; Jessica Reynolds; Donald Sykes; Bindukumar B Nair; Elaine Y Lin; Paras N Prasad; Stanley A Schwartz
Journal:  Curr HIV Res       Date:  2010-07       Impact factor: 1.581

Review 3.  Nanoparticulate systems for drug delivery and targeting to the central nervous system.

Authors:  Emanuela Fabiola Craparo; Maria Luisa Bondì; Giovanna Pitarresi; Gennara Cavallaro
Journal:  CNS Neurosci Ther       Date:  2010-10-15       Impact factor: 5.243

Review 4.  Targeting specific cells in the brain with nanomedicines for CNS therapies.

Authors:  Fan Zhang; Yi-An Lin; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  J Control Release       Date:  2015-12-11       Impact factor: 9.776

Review 5.  Drug transport to brain with targeted nanoparticles.

Authors:  Jean-Christophe Olivier
Journal:  NeuroRx       Date:  2005-01

Review 6.  Blood-brain barrier transport of therapeutics via receptor-mediation.

Authors:  Angela R Jones; Eric V Shusta
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

Review 7.  Getting into the brain: approaches to enhance brain drug delivery.

Authors:  Mayur M Patel; Bhoomika R Goyal; Shraddha V Bhadada; Jay S Bhatt; Avani F Amin
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

8.  Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line.

Authors:  Niladri Chattopadhyay; Jason Zastre; Ho-Lun Wong; Xiao Yu Wu; Reina Bendayan
Journal:  Pharm Res       Date:  2008-05-31       Impact factor: 4.200

Review 9.  Biomaterials for the central nervous system.

Authors:  Yinghui Zhong; Ravi V Bellamkonda
Journal:  J R Soc Interface       Date:  2008-09-06       Impact factor: 4.118

Review 10.  Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS.

Authors:  Gabriel A Silva
Journal:  BMC Neurosci       Date:  2008-12-10       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.